Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway

References

• Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010;122: 2451–2455.
   PubMed Web of Science ®Google Scholar
• Aslanger E, Uslu B, Akdeniz C, et al. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012;23:265–270.
   PubMed Web of Science ®Google Scholar
• Lee HC, Sheu SH, Liu IH, et al. Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol. 2012;25:56–62.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Yano T, Sendo T, et al. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci. 2005;97:473–488.
   PubMed Web of Science ®Google Scholar
• Emch TM, Haller NA. A randomized trial of prophylactic acetylcysteine and theophylline compared with placebo for the prevention of renal tubular vacuolization in rats after iohexol administration. Acad Radiol. 2003;10:514–519.
   PubMed Web of Science ®Google Scholar
• Meschi M, Detrenis S, Musini S, et al. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med. 2006;34:2060–2068.
   PubMed Web of Science ®Google Scholar
• Koc F, Ozdemir K, Kaya MG, , et al. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS – a multicenter prospective controlled trial. Int J Cardiol. 2012;l 155:418–423.
   PubMed Web of Science ®Google Scholar
• Al-Otaibi KE, Al Elaiwi AM, Tariq M, et al. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev. 2012;2012:831748.
   PubMed Web of Science ®Google Scholar
• Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy inpatients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN) atorvastatin for reduction of myocardial damage during angioplasty contrast–induced nephropathy trial. Am J Cardiol. 2011;108:1–7.
   PubMed Web of Science ®Google Scholar
• Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843–849.
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101: 279–285.
   PubMed Web of Science ®Google Scholar
• Zhao JL, Yang YJ, Zhang YH, et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol. 2008;126:435–436.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63:62–70.
   PubMed Web of Science ®Google Scholar
• Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008–3016.
   PubMed Web of Science ®Google Scholar
• Zhang T, Shen LH, Hu LH, et al. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011;33:344–351.
   PubMed Web of Science ®Google Scholar
• Furuichi K, Wada T, Iwata Y, et al. Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant. 2002;17:399–407.
   PubMed Web of Science ®Google Scholar
• Michael W, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30:1–10.
   PubMed Web of Science ®Google Scholar
• Clark L, Dewald B, Geiser T, et al. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA. 1993;90:3574–3577.
   PubMed Web of Science ®Google Scholar
• Heyman SN, Rosen S, Khamaisi M, et al. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol. 2010;45:188–195.
   PubMed Web of Science ®Google Scholar
• Asif A, Preston RA, Roth D. Contrast-induced nephropathy. Am J Ther. 2003;10:137–147.
   PubMedGoogle Scholar
• Efrati S, Berman S, Ilgiyeav I, et al. Differential effects of N-acetylcysteine, theophylline or bicarbonate on contrast-induced rat renal vasoconstriction. Am J Nephrol. 2009;29:181–191.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Pissas G, Liakopoulos V, et al. Toll-like receptors and their role in renal pathologies. Inflamm Allergy Drug Targets. 2012;11:464–477.
   PubMedGoogle Scholar
• Gluba A, Banach M, Hannam S, et al. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6:224–235.
   PubMed Web of Science ®Google Scholar
• Pulskens WP, Teske GJ, Butter LM, et al. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. Plos One. 2008;3:e3596
   PubMed Web of Science ®Google Scholar
• Shimada M, Ishimoto T, Lee PY, et al. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway . Nephrol Dial Transplant. 2012;27:81–89.
   PubMed Web of Science ®Google Scholar
• Goodman AI, Olszanecki R, Yang LM, et al. Heme oxygenase-1 protects against radio contrast-induced acute kidney injury by regulating anti-apoptotic proteins. Kidney Int. 2007;72:945–953.
   PubMed Web of Science ®Google Scholar